7. 26
symposium
Srinagarind Med J 2011: 26 (Suppl)
การประชุมวิชาการ ครั้งที่ 27 ประจ�ำปี 2554
เอกสารอ้างอิง
1. Trakultivakorn M, Sangsupawanich P, Vichyanond P.
Time trends of the prevalence of asthma, rhinitis and
eczema in Thai children-ISAAC (International Study
of Asthma and Allergies in Childhood) Phase Three.
J Asthma 2007; 44:609-11.
2. Vichyanond P, Sunthornchart S, Singhirannusorn V,
RuangratS,KaewsomboonS,VisitsunthornN.Prevalence
ofasthma,allergicrhinitisandeczemaamonguniversity
students in Bangkok. Respir Med 2002; 96:34-8.
3. Bunnag C, Kongpatanakul S, Jareoncharsri P,
Voraprayoon S, Supatchaipisit P. A survey of allergic
diseases in university students of Bangkok, Thailand.
J Rhinol 1997; 4:90-3.
4. Fireman P. Therapeutic approaches to allergic rhinitis:
treatingthechild.JAllergyClinImmunol2000;105(6Pt2):
S616-21.
5. KuligM,KlettkeU,WahnV,ForsterJ,BauerCP,WahnU.
Development of seasonal allergic rhinitis during the
first 7 years of life. J Allergy Clin Immunol 2000;
106:832-9.
6. BousquetJ,BullingerM,FayolC,MarquisP,ValentinB,
Burtin B. Assessment of quality of life in patients with
perennial allergic rhinitis with the French version of
the SF-36 Health Status Questionnaire. J Allergy Clin
Immunol 1994; 94(2 Pt 1):182-8.
7. Leynaert B, Neukirch F, Demoly P, Bousquet J.
Epidemiologic evidence for asthma and rhinitis
comorbidity.JAllergyClinImmunol2000;106(5Suppl):
S201-5.
8. Linneberg A, Henrik Nielsen N, Frolund L, Madsen F,
DirksenA,JorgensenT.Thelinkbetweenallergicrhinitis
and allergic asthma: a prospective population-based
study. The Copenhagen Allergy Study. Allergy 2002;
57:1048-52.
ตารางที่ 1 สรุปยาที่ใช้รักษาโรคจมูกอักเสบภูมิแพ้69, 70
ชื่อยา ประเภทของยา
ตามความเสี่ยงของตัวอ่อน/ทารก
อายุที่แนะน�ำให้ใช้
INTRANASAL CORTICOSTEROIDS
Beclomethasone B 6 ปี
Budesonide C 6 ปี
Fluticasone propionate C 4
Triamcinolone C 2
Fluticasone furoate C 2
Mometasone C 2
ORAL ANTIHISTAMINES
Cetirizine B 2 ปี
Desloratadine C 6 เดือน
Fexofenadine C 6 เดือน
Levocetirizine B 6 ปี
Loratadine B 2 ปี
DECONGESTANTS
Pseudoephedrine C 2 ปี
Oxymetazoline C 6 เดือน
ANTI-CHOLINERGIC
Ipratropium B 6 ปี
CROMONE
Cromolyn B 2 ปี
ANTI-LEUKOTRIENE
Montelukast B 6 เดือน
8. 27
symposium
Srinagarind Med J 2011: 26 (Suppl)
การประชุมวิชาการ ครั้งที่ 27 ประจ�ำปี 2554
9. BousquetJ,Annesi-MaesanoI,CaratF,LegerD,RuginaM,
Pribil C, et al. Characteristics of intermittent and
persistent allergic rhinitis: DREAMS study group. Clin
Exp Allergy 2005; 35:728-32.
10. BousquetJ,KhaltaevN,CruzAA,DenburgJ,FokkensWJ,
TogiasA,etal.AllergicRhinitisanditsImpactonAsthma
(ARIA) 2008 update (in collaboration with the World
Health Organization, GA(2)LEN and AllerGen). Allergy
2008; 63 Suppl 86:8-160.
11. SheikhA,HurwitzB,ShehataY.Housedustmiteavoidance
measures for perennial allergic rhinitis. Cochrane
Database Syst Rev 2007:CD001563.
12. TerreehorstI,HakE,OostingAJ,Tempels-PavlicaZ,de
Monchy JG, Bruijnzeel-Koomen CA, et al. Evaluation of
impermeablecoversforbeddinginpatientswithallergic
rhinitis. N Engl J Med 2003; 349:237-46.
13. Wood RA, Johnson EF, Van Natta ML, Chen PH,
Eggleston PA. A placebo-controlled trial of a HEPA air
cleaner in the treatment of cat allergy. Am J Respir Crit
Care Med 1998; 158:115-20.
14. Pinar E, Eryigit O, Oncel S, Calli C, Yilmaz O, Yuksel H.
Efficacyofnasalcorticosteroidsaloneorcombinedwith
antihistamines or montelukast in treatment of allergic
rhinitis. Auris Nasus Larynx 2008; 35:61-6.
15. YanivE,HadarT,ShveroJ,TamirR,NagerisB.KTP/532
YAG laser treatment for allergic rhinitis. Am J Rhinol
Allergy 2009; 23:527-30.
16. TsaiYL,SuCC,LeeHS,ChenHC,ChenMK.Symptoms
treatment for allergic rhinitis using diode laser: results
after 6-year follow-up. Lasers Med Sci 2009; 24:230-3.
17. Siegel GJ, Seiberling KA, Haines KG, Aguado AS.
OfficeCO2laserturbinoplasty.EarNoseThroatJ2008;
87:386-90.
18. LiuCM,TanCD,LeeFP,LinKN,HuangHM.Microdebrider-
assisted versus radiofrequency-assisted inferior
turbinoplasty. Laryngoscope 2009; 119:414-8.
19. Cavaliere M, Mottola G, Iemma M. Comparison of the
effectivenessandsafetyofradiofrequencyturbinoplasty
andtraditionalsurgicaltechniqueintreatmentofinferior
turbinate hypertrophy. Otolaryngol Head Neck Surg
2005; 133:972-8.
20. Lin HC, Lin PW, Su CY, Chang HW. Radiofrequency for
the treatment of allergic rhinitis refractory to medical
therapy. Laryngoscope 2003; 113:673-8.
21. Gunhan K, Unlu H, Yuceturk AV, Songu M. Intranasal
steroids or radiofrequency turbinoplasty in persistent
allergic rhinitis: effects on quality of life and objective
parameters.EurArchOtorhinolaryngol2011;268:845-50.
22. Chen YL, Tan CT, Huang HM. Long-term efficacy
of microdebrider-assisted inferior turbinoplasty with
lateralization for hypertrophic inferior turbinates in
patients with perennial allergic rhinitis. Laryngoscope
2008; 118:1270-4.
23. Greywoode JD, Van Abel K, Pribitkin EA. Ultrasonic
bone aspirator turbinoplasty: a novel approach for
management of inferior turbinate hypertrophy.
Laryngoscope 120 Suppl 4:S239.
24. Simons FE. Advances in H1-antihistamines. N Engl J
Med 2004; 351:2203-17.
25. Togias AG, Naclerio RM, Warner J, Proud D,
Kagey-Sobotka A, Nimmagadda I, et al. Demonstration
of inhibition of mediator release from human mast cells
byazatadinebase.Invivoandinvitroevaluation.JAMA.
1986; 255:225-9.
26. Baroody FM, Lim MC, Proud D, Kagey-Sobotka A,
Lichtenstein LM, Naclerio RM. Effects of loratadine and
terfenadineontheinducednasalallergicreaction.Arch
Otolaryngol Head Neck Surg 1996 122:309-16.
27. Naclerio RM, Proud D, Kagey-Sobotka A, Freidhoff L,
Norman PS, Lichtenstein LM. The effect of cetirizine
on early allergic response. Laryngoscope 1989;
99(6 Pt 1):596-9.
28. Campbell A, Chanal I, Czarlewski W, Michel FB,
BousquetJ.ReductionofsolubleICAM-1levelsinnasal
secretion by H1-blockers in seasonal allergic rhinitis.
Allergy 1997; 52:1022-5.
29. Bascom R, Wachs M, Naclerio RM, Pipkorn U, Galli SJ,
Lichtenstein LM. Basophil influx occurs after nasal
antigen challenge: effects of topical corticosteroid
pretreatment. J Allergy Clin Immunol 1988; 81:580-9.
30. Pipkorn U, Proud D, Lichtenstein LM, Kagey-Sobotka
A, Norman PS, Naclerio RM. Inhibition of mediator
release in allergic rhinitis by pretreatment with topical
glucocorticosteroids.NEnglJMed1987;316:1506-10.
9. 28
symposium
Srinagarind Med J 2011: 26 (Suppl)
การประชุมวิชาการ ครั้งที่ 27 ประจ�ำปี 2554
31. ChristodoulopoulosP,CameronL,DurhamS,HamidQ.
Molecular pathology of allergic disease. II: Upper
airwaydisease.JAllergyClinImmunol2000;105(2Pt1):
211-23.
32. RatnerPH,PaullBR,FindlaySR,HampelF,Jr.,MartinB,
Kral KM, et al. Fluticasone propionate given once
daily is as effective for seasonal allergic rhinitis as
beclomethasone dipropionate given twice daily.
J Allergy Clin Immunol 1992; 90(3 Pt 1):285-91.
33. vanAsA,BronskyEA,DockhornRJ,GrossmanJ,Lumry
W, Meltzer EO, et al. Once daily fluticasone propionate
isaseffectiveforperennialallergicrhinitisastwicedaily
beclomethasone diproprionate. J Allergy Clin Immunol
1993; 91:1146-54.
34. Yanez A, Rodrigo GJ. Intranasal corticosteroids versus
topical H1 receptor antagonists for the treatment of
allergic rhinitis: a systematic review with meta-analysis.
Ann Allergy Asthma Immunol 2002; 89:479-84.
35. Weiner JM, Abramson MJ, Puy RM. Intranasal
corticosteroids versus oral H1 receptor antagonists
in allergic rhinitis: systematic review of randomised
controlled trials. BMJ 1998; 317:1624-9.
36. BernsteinDI,LevyAL,HampelFC,BaidooCA,CookCK,
Philpot EE, et al. Treatment with intranasal fluticasone
propionate significantly improves ocular symptoms in
patients with seasonal allergic rhinitis. Clin Exp Allergy
2004; 34:952-7.
37. DeWesterJ,PhilpotEE,WestlundRE,CookCK,Rickard
KA. The efficacy of intranasal fluticasone propionate in
the relief of ocular symptoms associated with seasonal
allergic rhinitis. Allergy Asthma Proc 2003; 24:331-7.
38. Wilson AM, O‘Byrne PM, Parameswaran K. Leukotriene
receptor antagonists for allergic rhinitis: a systematic
reviewandmeta-analysis.AmJMed2004;116:338-44.
39. Derendorf H, Meltzer EO. Molecular and clinical
pharmacologyofintranasalcorticosteroids:clinicaland
therapeutic implications. Allergy 2008; 63:1292-300.
40. AllenDB,MeltzerEO,LemanskeRFJr,PhilpotEE,Faris
MA, Kral KM, et al. No growth suppression in children
treated with the maximum recommended dose of
fluticasonepropionateaqueousnasalsprayforoneyear.
Allergy Asthma Proc 2002; 23:407-13.
41. Schenkel EJ, Skoner DP, Bronsky EA, Miller SD,
Pearlman DS, Rooklin A, et al. Absence of growth
retardationinchildrenwithperennialallergicrhinitisafter
oneyearoftreatmentwithmometasonefuroateaqueous
nasal spray. Pediatrics 2000; 105:E22.
42. Dykewicz MS, Kaiser HB, Nathan RA, Goode-Sellers S,
Cook CK, Witham LA, et al. Fluticasone propionate
aqueous nasal spray improves nasal symptoms of
seasonal allergic rhinitis when used as needed (prn).
Ann Allergy Asthma Immunol 2003; 91:44-8.
43. Philip G, Malmstrom K, Hampel FC, Weinstein SF,
LaForce CF, Ratner PH, et al. Montelukast for treating
seasonal allergic rhinitis: a randomized, double-blind,
placebo-controlled trial performed in the spring. Clin
Exp Allergy 2002; 32:1020-8.
44. van Adelsberg J, Philip G, Pedinoff AJ, Meltzer EO,
Ratner PH, Menten J, et al. Montelukast improves
symptoms of seasonal allergic rhinitis over a 4-week
treatment period. Allergy 2003; 58:1268-76.
45. van Adelsberg J, Philip G, LaForce CF, Weinstein SF,
Menten J, Malice MP, et al. Randomized controlled trial
evaluatingtheclinicalbenefitofmontelukastfortreating
spring seasonal allergic rhinitis. Ann Allergy Asthma
Immunol 2003; 90:214-22.
46. CiebiadaM,Gorska-CiebiadaM,DuBuskeLM,GorskiP.
Montelukast with desloratadine or levocetirizine for
the treatment of persistent allergic rhinitis. Ann Allergy
Asthma Immunol 2006; 97:664-71.
47. LagosJA,MarshallGD.Montelukastinthemanagement
ofallergicrhinitis.TherClinRiskManag2007;3:327-32.
48. Li AM, Abdullah VJ, Tsen CS, Au CT, Lam HS, So HK,
et al. Leukotriene receptor antagonist in the treatment
of childhood allergic rhinitis--a randomized placebo-
controlled study. Pediatr Pulmonol 2009; 44:1085-92.
49. PhilipG,Williams-HermanD,PatelP,WeinsteinSF,Alon
A, Gilles L, et al. Efficacy of montelukast for treating
perennial allergic rhinitis. Allergy Asthma Proc 2007;
28:296-304.
50. Prenner B, Anolik R, Danzig M, Yao R. Efficacy and
safety of fixed-dose loratadine/montelukast in seasonal
allergic rhinitis: effects on nasal congestion. Allergy
Asthma Proc 2009; 30:263-9.
10. 29
symposium
Srinagarind Med J 2011: 26 (Suppl)
การประชุมวิชาการ ครั้งที่ 27 ประจ�ำปี 2554
51. Kaiser HB, Findlay SR, Georgitis JW, Grossman J,
Ratner PH, Tinkelman DG, et al. The anticholinergic
agent, ipratropium bromide, is useful in the treatment
of rhinorrhea associated with perennial allergic rhinitis.
Allergy Asthma Proc 1998; 19:23-9.
52. Mygind N, Borum P. Intranasal ipratropium: literature
abstracts and comments. Rhinol Suppl. 1989; 9:37-44.
53. ScaddingGK,DurhamSR,MirakianR,JonesNS,LeechSC,
FarooqueS,etal.BSACIguidelinesforthemanagement
of allergic and non-allergic rhinitis. Clin Exp Allergy
2008; 38:19-42.
54. KernanWN,ViscoliCM,BrassLM,BroderickJP,BrottT,
FeldmannE,etal.Phenylpropanolamineandtheriskof
hemorrhagic stroke. N Engl J Med 2000; 343:1826-32.
55. Chang TW. The pharmacological basis of anti-IgE
therapy.NatBiotech[101038/72601].2000;18:157-62.
56. Bousquet JHU, Chung KF, Oshinyemi K, Blogg M.
Omalizumab improves symptom control in patients
with poorly controlled allergic asthma and concomitant
rhinitis. 2003; 111:A295.
57. Vignola AM, Humbert M, Bousquet J, Boulet LP,
Hedgecock S, Blogg M, et al. Efficacy and tolerability
of anti-immunoglobulin E therapy with omalizumab in
patientswithconcomitantallergicasthmaandpersistent
allergic rhinitis: SOLAR. Allergy 2004; 59:709-17.
58. ChervinskyP,CasaleT,TownleyR,TripathyI,HedgecockS,
Fowler-Taylor A, et al. Omalizumab, an anti-IgE
antibody,inthetreatmentofadultsandadolescentswith
perennialallergicrhinitis.AnnAllergyAsthmaImmunol.
2003; 91:160-7.
59. Kuehr J, Brauburger J, Zielen S, Schauer U, Kamin W,
VonBergA,etal.Efficacyofcombinationtreatmentwith
anti-IgE plus specific immunotherapy in polysensitized
childrenandadolescentswithseasonalallergicrhinitis.
J Allergy Clin Immunol 2002; 109:274-80.
60. Passalacqua G, Durham SR. Allergic rhinitis and its
impact on asthma update: allergen immunotherapy.
J Allergy Clin Immunol 2007; 119:881-91.
61. LichtensteinLM,HoltzmanNA,BurnettLS.Aquantitative
in vitro study of the chromatographic distribution and
immunoglobulin characteristics of human blocking
antibody. J Immunol 1968; 101:317-24.
62. GleichGJ,ZimmermannEM,HendersonLL,YungingerJW.
Effect of immunotherapy on immunoglobulin E and
immunoglobulin G antibodies to ragweed antigens:
a six-year prospective study. J Allergy Clin Immunol.
1982; 70:261-71.
63. DesRochesA,ParadisL,KnaniJ,HejjaouiA,DhivertH,
Chanez P, et al. Immunotherapy with a standardized
Dermatophagoides pteronyssinus extract. V. Duration
of the efficacy of immunotherapy after its cessation.
Allergy 1996; 51:430-3.
64. Durham SR, Walker SM, Varga EM, Jacobson MR,
O‘Brien F, Noble W, et al. Long-term clinical efficacy
of grass-pollen immunotherapy. N Engl J Med 1999;
341:468-75.
65. Wilson DR, Lima MT, Durham SR. Sublingual
immunotherapy for allergic rhinitis: systematic review
and meta-analysis. Allergy 2005; 60:4-12.
66. Filliaci F, Zambetti G, Romeo R, Ciofalo A, Luce M,
GermanoF.Non-specifichyperreactivitybeforeandafter
nasal specific immunotherapy. Allergol Immunopathol
(Madr) 1999; 27:24-8.
67. GuptaP,SaltounC.Allergenimmunotherapy:definition,
indication, and reactions. Allergy Asthma Proc 2004;
25(4 Suppl 1):S7-8.
68. ฉวีวรรณบุนนาค,พีรพันธ์เจริญชาศรี,ประยุทธตันสุริยวงศ์,
ปารยะ อาศนะเสน, ศิริพร วรประยูร, เผด็จ เดชพันพัว,
และคณะ ปฎิกิริยาไม่พึงประสงค์ที่เกิดจากการฉีดสารก่อ
ภูมิแพ้ : ประสบการณ์ในการโรงพยาบาลศิริราช. สารศิริราช
2545; 54:517-24.
69. Sur DK, Scandale S. Treatment of allergic rhinitis.
Am Fam Physician. 2011; 81:1440-6.
70. Yawn B, Knudtson M. Treating asthma and comorbid
allergic rhinitis in pregnancy. J Am Board Fam Med.
2007; 20:289-98.